Valuation: Relay Therapeutics, Inc.

Market Cap 431.49Cr 387.13Cr 357.92Cr 324.16Cr 605.61Cr 41TCr 612.93Cr 4.28TCr 1.7TCr 22TCr 1.62TCr 1.59TCr 68TCr P/E 2026 *
-12.3x
P/E 2027 * -12.2x
Enterprise Value 374.42Cr 335.93Cr 310.58Cr 281.28Cr 525.51Cr 36TCr 531.86Cr 3.71TCr 1.48TCr 19TCr 1.41TCr 1.38TCr 59TCr EV / Sales 2026 *
335x
EV / Sales 2027 * 216x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week+7.20%
Current month+8.92%
1 month+7.08%
3 months+7.02%
6 months+56.40%
Current year+132.39%
1 week 17.68
Extreme 17.68
20.2
1 month 16.13
Extreme 16.13
20.2
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
06/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
08/09/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%+7.20%+168.95%+215.57% 431.49Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+0.98%+2.68%+12.25%+83.90% 5.55TCr
+1.75%+2.01%+13.30%+105.71% 5.3TCr
-1.48%-0.79%+26.76%+55.86% 4.6TCr
-0.80%-2.81%+18.00%+99.08% 4.25TCr
+0.34%+0.96%+226.61%+932.70% 4.04TCr
-0.26%-4.20%+10.86%+45.18% 3.23TCr
-2.07%+42.73%+103.77%+90.26% 3.45TCr
-2.72%-8.79%+22.58%-5.63% 2.42TCr
Average -0.46%+4.14%+64.05%+168.37% 3.97TCr
Weighted average by Cap. -0.20%+3.17%+50.78%+161.38%

Financials

2026 *2027 *
Net sales 1.12Cr 1Cr 92.78L 84.03L 1.57Cr 106.53Cr 1.59Cr 11Cr 4.42Cr 56Cr 4.2Cr 4.11Cr 176.97Cr 1.79Cr 1.61Cr 1.49Cr 1.35Cr 2.51Cr 170.6Cr 2.54Cr 18Cr 7.08Cr 89Cr 6.72Cr 6.58Cr 283.41Cr
Net income -32Cr -29Cr -27Cr -24Cr -45Cr -3.05TCr -45Cr -317.49Cr -126.46Cr -1.6TCr -120.13Cr -117.59Cr -5.06TCr -35Cr -31Cr -29Cr -26Cr -49Cr -3.31TCr -49Cr -344.47Cr -137.2Cr -1.73TCr -130.34Cr -127.59Cr -5.5TCr
Net Debt -57Cr -51Cr -47Cr -43Cr -80Cr -5.44TCr -81Cr -566Cr -225.44Cr -2.84TCr -214.16Cr -209.64Cr -9.03TCr -44Cr -40Cr -37Cr -33Cr -62Cr -4.21TCr -63Cr -438.36Cr -174.6Cr -2.2TCr -165.86Cr -162.36Cr -6.99TCr
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
29/26/29 $19.65 -0.20% 6,73,303
28/26/28 $19.69 +4.51% 28,08,741
27/26/27 $18.84 +3.97% 22,58,311
26/26/26 $18.12 -0.33% 15,85,748
23/26/23 $18.18 -0.87% 18,98,940
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
19.69USD
Average target price
27.58USD
Spread / Average Target
+40.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock